![]() |
市場調查報告書
商品編碼
1284257
到 2028 年的輸液泵軟件市場預測——按類型(臨床工作流程軟件、減少劑量錯誤軟件、互操作性軟件)、按適應症、按應用、按最終用戶、按地區分類的全球分析Infusion Pump Software Market Forecasts to 2028 - Global Analysis By Type (Clinical Workflow Software, Dose Error Reduction Software and Interoperability Software), Indication, Application, End User and By Geography |
根據 Stratistics MRC 的數據,2022 年全球輸液泵軟件市場將達到 9.635 億美元,預計到 2028 年將達到 16.249 億美元,預計複合年增長率為 9.1 2020 年的百分比。
一組稱為輸液泵的泵用於輸送藥物和營養物質等物質。 該軟件控制液體傳輸的速度。 該軟件還控制泵送機制和用戶界面,以在安全等關鍵任務中保持同步。 該泵是一個外部設備。 泵通過動脈、靜脈和皮下通路輸送這些液體。 隨著外科手術數量的增加,輸液泵在這些國家的機會也在增加,這最終推動了對輸液泵所用軟件的需求。
根據《傳染病顧問雜誌》,美國每年進行大約 2700 萬次外科手術。
慢性病的增加和醫院液體治療成本的上升導致家庭輸液解決方案的研發活動激增。 例如,越來越多的糖尿病、癌症和神經系統疾病患者需要長期護理,最好是在家中。 此外,老齡化社會對長期護理的需求正在推動針對家庭輸液治療的新產品的開發。
關於泵的製造和使用的法規正在收緊,從而減緩了新設備的審批流程。 因此,預計市場的擴張將被推遲。 此外,由於製造錯誤導致產品召回的增加也阻礙了市場擴張。 例如,2019 年 8 月,由於輸液警報、低優先級保持靜脈開放 (KVO) 和多個軟件錯誤,我們召回了 Vigilant Agilia 藥物庫和 Volume MC Agilia 輸液泵。
門診泵是各種醫療環境中給藥的重要工具。 在對醫院和家中的患者進行止痛藥、化學療法、液體和其他治療時,它是必不可少的。 在發達國家,隨著在現場進行長期護理以減輕與醫院管理相關的經濟限制,預計在不久的將來門診泵的市場將會增長。
單位、10 的倍數、計算錯誤和按鈕錯誤是最常見的輸液問題。 在對輸液泵進行編程時,少量錯別字可能會造成災難性後果。 為了解決這些問題並將當前的智能泵推進到一個新的“智能”輸液系統水平,輸液泵和條碼藥物管理(BCMA)系統、醫院信息系統(HIS)、電子病歷(EMR))需要無線連接。 由於無線連接不佳和醫院支出限制,大多數醫院的智能輸液設備和醫院信息系統不兼容,輸液泵市場面臨重大障礙。
COVID-19 大流行的影響及其持續時間的不確定性顯著提高了該行業的增長率。 2020 年 COVID-19 測試的增加在很大程度上是罪魁禍首。 然而,COVID-19 疫情導致勞動力短缺和供應鏈中斷,導致產量下降。 主要利益相關者不斷改變策略以應對快速變化的情況。 預計醫療保健行業將受到 COVID-19 的嚴重長期影響。 在這個問題得到解決之前,各國和利益相關者需要將醫療改革作為優先事項。
胰島素輸注部分預計將實現有利可圖的增長,因為它以顯著更高的增長率增長並保持其主導地位。 這是由於全球 1 型糖尿病患者的數量不斷增加,以及胰島素泵領域的技術發展前景廣闊。 未來幾年,PCA 泵在疼痛治療中的廣泛使用預計將增加全球產品需求。
由於最昂貴的輸液設備、使用這些設施的患者數量巨大以及操作泵的熟練員工的可用性,預計醫院部門在預測期內將以最快的複合年增長率增長。以及醫院部門佔據最大的市場份額。 然而,由於門診泵的使用增加以及對護理點管理以減輕成本負擔的需求不斷增長,家庭護理環境領域的份額正在增加。
北美輸液泵軟件市場目前的擴張意義重大,因為家庭醫療保健行業、患者和醫生不斷採用新的尖端解決方案來進行慢性病的常規管理。被認為是負責任的,預計將保持預測期內的最高市場份額。 由於患者意識的提高、慢性病患病率上升、手術數量增加以及控制不斷上升的醫療保健成本的需要,輸液泵軟件在該地區經歷了顯著增長。
預計亞太地區將在預測期內呈現最高的複合年增長率。 然而,隨著主要公司專注於進一步擴大其基地,預計這些地區的市場將擴大。
2023 年 5 月,百特簽署了最終協議,以 42.5 億美元的價格將其生物製藥解決方案業務出售給 Advent International 和 Warburg Pincus。
2023 年 4 月,百特將在美國推出 Zosyn Premix。 Zosyn Premix 適用於治療由敏感細菌引起的多重感染,並以 Baxter 獨有的單劑量 Galaxy 容器提供。
According to Stratistics MRC, the Global Infusion Pump Software Market is accounted for $963.5 million in 2022 and is expected to reach $1,624.9 million by 2028 growing at a CAGR of 9.1% during the forecast period. A group of pumps called infusion pumps are used to transport substances like medications and nutrition. Software controls the rates at which the fluids are transferred. The software also controls the pumping mechanism to maintain the pace and the user interface, among other crucial tasks like safety. These pumps are outside equipment. The pump moves these fluids through arterial, intravenous, and subcutaneous pathways. This rising trend of the number of surgical procedures performed is indicating that there is a growing opportunity for the infusion pumps in such countries which is ultimately driving the demand for the software used for infusion pump.
According to the Journal of Infectious Disease Adviser, approximately 27 million surgical procedures are performed in the United States each year.
Growing research and development efforts are being made to create home-based infusion solutions as a result of the rising prevalence of chronic illnesses and the rising expense of hospital-based infusion therapies. For instance, an increasing number of people with diabetes, cancer, and neurological illnesses are in need of long-term care, preferably at home. Furthermore, the necessity for long-term care therapies among an ageing population is fuelling the development of new products aimed at home-based infusion therapies.
Regulations governing the manufacture and use of pumps are becoming more onerous, which slows down the approval process for new devices. This aspect is projected to slow market expansion. Additionally, a growing number of product recalls brought on by manufacturing mistakes are limiting market expansion. For example, recalled the Vigilant Agilia drug library and the Volume MC Agilia infusion pump in August 2019 due to infusion alarm, low priority keep vein open (KVO), and multiple software errors.
An important tool for medication administration in a variety of medical settings is the ambulatory pump. They are essential in giving patients analgesics, chemotherapy, TPN infusions, and other treatments in hospitals and at home. The market for portable pumps is projected to rise in the near future due to the move towards site of care management of chronic illnesses in industrialised nations in order to reduce the financial constraints associated with hospital-based management.
Unit, multiples of ten, computation, and push-button errors are some of the most typical infusion problems. When programming infusion pumps, decimal entry mistakes can have fatal consequence to address these issues and advance the present smart pumps to a new level of "intelligent" infusion systems, wireless connection of infusion pumps with the Barcoded Medication Administration (BCMA) system, the Hospital Information System (HIS), and the Electronic Medical Record (EMR) is necessary. The market for infusion pumps faces a substantial obstacle from the lack of compatibility between smart infusion devices and hospital information systems in most hospitals as a result of poor wireless connectivity and limited hospital spending.
The COVID-19 pandemic's effects and the uncertainty surrounding its longevity have caused a significant increase in the industry's growth rate. The rise in COVID-19 testing in 2020 is mostly to blame for this. However, there was a reduction in output as a result of the COVID-19 epidemic due to labour shortages and supply chain interruptions. Important parties are continuing to modify their tactics in response to the fast shifting circumstances. The healthcare sector is expected to see severe long-term effects from COVID-19. Prioritised healthcare reforms would need to be implemented by nations and significant stakeholders until the issue is resolved.
The insulin infusion segment is estimated to have a lucrative growth, due to increase at a noticeably high growth rate, maintaining its dominance. This is due to an increase in the number of type 1 diabetes patients worldwide and the development of promising technology in the area of insulin pumps. In the upcoming years, expanding PCA pump uses in pain treatment are projected to increase product demand globally.
The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the most expensive infusion devices, huge patient population using these facilities, and availability of skilled staff to operate the pump, the hospitals sector held the greatest share of the market. However, due to the rising use of ambulatory pumps and growing demand for site of care management to lower cost burden, the home care settings segment.
North America is projected to hold the highest market share during the forecast period owing to the home healthcare industry, patients, and doctors are largely to blame for the present expansion of the North American infusion pump software market as they consistently embrace new, cutting-edge solutions for the routine management of chronic medical conditions. Infusion pump software has seen significant growth in the region due to increased patient awareness, the rising prevalence of chronic diseases, and an increase in the number of surgeries performed there, and the need to rein in rising healthcare costs.
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to some of the factors include the rise in the prevalence of chronic diseases like diabetes and cancer, expanding healthcare infrastructure, growing GDP, an increase in disposable income, and rising awareness of the accessibility of advanced therapies in the Asia Pacific region. However, the market in these regions will grow as major firms focus more on expanding their footprint.
Some of the key players profiled in the Infusion Pump Software Market include Baxter International, Becton, Dickinson and Company, B. Braun Medical Inc., FLOWONIX MEDICAL INC, Medtronic, Merck KGaA, Smiths Medical, Q Core Medical Ltd, Fresenius Kabi, ICU Medical Inc., Roche Diagnostics, Agilent Technologies, Terumo Medical, Micrel Medical Devices, Ypsomed and F. Hoffmann-La Roche
In May 2023, Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion.
In April 2023, Baxter Launches Zosyn Premix in US, Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter's proprietary single-dose Galaxy containers.